

Notes:

1. The figures have been re-grouped, re-casted and re-arranged wherever necessary.
2. The financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meetings held on 31st October, 2013.
3. As per clause 41 of the listing agreement, the Company has opted to publish only consolidated financial results. The stand-alone financial results are available for perusal on the Company's website as well as on the stock exchanges' websites as stated below: www.dishmangroup.com, www.bseindia.com, and www.nse-india.com
4. The Statutory Auditors have carried out a "Limited Review" of the stand-alone financial results of the Company for the quarter ended 30th September, 2013.
5. Details of Number of Investor complaints for the quarter ended 30th September, 2013: beginning - NIL, received- 7, resolved – 7, pending- NIL as at 30th September, 2013.
6. A Survey was carried out by the Income Tax Department under the provision of Section 133A of Income Tax Act, 1961 in the factory and office premises of the Company on 10/10/2013, which was concluded on 11/10/2013. The Department has sought various information and explanations and the Company has provided the same. The Company does not expect any significant additional tax liability to emanate from the survey findings.
7. The business segments of the Company comprise the followings:

Segment	Description of the activity
CRAMS	Contract Research and Manufacturing Segment under long term supply agreements
OTHERS	Bulk Drugs, Intermediates, Quats, Speciality Chemicals and Traded Goods

8. Consolidated financial results comprise the results of the parent Company, Dishman Pharmaceuticals and Chemicals Limited and its subsidiaries viz. Dishman Europe Limited., Dishman USA Inc., Dishman International Trading (Shanghai) Co. Ltd., Dishman Switzerland Limited, Dishman Pharma Solutions AG, Switzerland, Dishman Pharmaceuticals & Chemicals (Shanghai) Co. Ltd., Innovative Ozone Services Inc. (IO₃S), Dishman Netherlands B. V. (formerly known as "Pharma Syn B. V."), Cohecie Fine Chemicals B.V. (formerly known as "Dishman Holland B.V."), Carbogen Amcis Ltd. (formerly known as "Synprotec DCR Ltd."), CARBOGEN AMCIS AG, Carbogen Amcis (India) Limited, Dishman Australasia Pty. Ltd., Dishman Care Ltd., Dishman Middle East (FZE), Dishman Japan Limited (85% holding by Dishman), two joint venture Companies., namely Schutz-Dishman Biotech Ltd.(22.33% holding by Dishman), and Dishman Arabia Ltd., (50% holding by Dishman) and one associate company namely, Bhadr-Raj Holdings Pvt. Ltd. (40% holding by Dishman) as per relevant Accounting Standards.

On behalf of the Board of Directors

Place: Ahmedabad
Date: 31st October, 2013

Arpit J. Vyas
Managing Director